88 related articles for article (PubMed ID: 10459584)
1. A surface-displayed cholera toxin B peptide improves antibody responses using food-grade staphylococci for mucosal subunit vaccine delivery.
Cano F; Liljeqvist S; Nguyen TN; Samuelson P; Bonnefoy JY; Ståhl S; Robert A
FEMS Immunol Med Microbiol; 1999 Aug; 25(3):289-98. PubMed ID: 10459584
[TBL] [Abstract][Full Text] [Related]
2. Chimeric plant virus particles administered nasally or orally induce systemic and mucosal immune responses in mice.
Brennan FR; Bellaby T; Helliwell SM; Jones TD; Kamstrup S; Dalsgaard K; Flock JI; Hamilton WD
J Virol; 1999 Feb; 73(2):930-8. PubMed ID: 9882293
[TBL] [Abstract][Full Text] [Related]
3. Induction of immune responses and prevention of alveolar bone loss by intranasal administration of mice with Porphyromonas gingivalis fimbriae and recombinant cholera toxin B subunit.
Takahashi Y; Kumada H; Hamada N; Haishima Y; Ozono S; Isaka M; Yasuda Y; Tochikubo K; Umemoto T
Oral Microbiol Immunol; 2007 Dec; 22(6):374-80. PubMed ID: 17949339
[TBL] [Abstract][Full Text] [Related]
4. Recombinant cholera toxin B subunit acts as an adjuvant for the mucosal and systemic responses of mice to mucosally co-administered bovine serum albumin.
Tochikubo K; Isaka M; Yasuda Y; Kozuka S; Matano K; Miura Y; Taniguchi T
Vaccine; 1998; 16(2-3):150-5. PubMed ID: 9607023
[TBL] [Abstract][Full Text] [Related]
5. Intranasal administration of recombinant Neisseria gonorrhoeae transferrin binding proteins A and B conjugated to the cholera toxin B subunit induces systemic and vaginal antibodies in mice.
Price GA; Russell MW; Cornelissen CN
Infect Immun; 2005 Jul; 73(7):3945-53. PubMed ID: 15972481
[TBL] [Abstract][Full Text] [Related]
6. Intranasal immunization of mice with group B streptococcal protein rib and cholera toxin B subunit confers protection against lethal infection.
Larsson C; Holmgren J; Lindahl G; Bergquist C
Infect Immun; 2004 Feb; 72(2):1184-7. PubMed ID: 14742572
[TBL] [Abstract][Full Text] [Related]
7. Induction and recall of immune memory by mucosal immunization with a non-toxic recombinant enterotoxin-based chimeric protein.
Gockel CM; Russell MW
Immunology; 2005 Dec; 116(4):477-86. PubMed ID: 16313361
[TBL] [Abstract][Full Text] [Related]
8. Protective immunity to Streptococcus mutans induced by nasal vaccination with surface protein antigen and mutant cholera toxin adjuvant.
Saito M; Otake S; Ohmura M; Hirasawa M; Takada K; Mega J; Takahashi I; Kiyono H; McGhee JR; Takeda Y; Yamamoto M
J Infect Dis; 2001 Mar; 183(5):823-6. PubMed ID: 11181162
[TBL] [Abstract][Full Text] [Related]
9. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
10. Intranasal immunization with lipoteichoic acid and cholera toxin evokes specific pharyngeal IgA and systemic IgG responses and inhibits streptococcal adherence to pharyngeal epithelial cells in mice.
Yokoyama Y; Harabuchi Y
Int J Pediatr Otorhinolaryngol; 2002 May; 63(3):235-41. PubMed ID: 11997159
[TBL] [Abstract][Full Text] [Related]
11. A recombinant P4 protein of Haemophilus influenzae induces specific immune responses biologically active against nasopharyngeal colonization in mice after intranasal immunization.
Hotomi M; Ikeda Y; Suzumoto M; Yamauchi K; Green BA; Zlotnick G; Billal DS; Shimada J; Fujihara K; Yamanaka N
Vaccine; 2005 Jan; 23(10):1294-300. PubMed ID: 15652672
[TBL] [Abstract][Full Text] [Related]
12. Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection.
Asahi-Ozaki Y; Itamura S; Ichinohe T; Strong P; Tamura S; Takahashi H; Sawa H; Moriyama M; Tashiro M; Sata T; Kurata T; Hasegawa H
Microbes Infect; 2006 Oct; 8(12-13):2706-14. PubMed ID: 16968669
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of a West Nile virus DIII-cholera toxin A2/B chimera after intranasal delivery.
Tinker JK; Yan J; Knippel RJ; Panayiotou P; Cornell KA
Toxins (Basel); 2014 Apr; 6(4):1397-418. PubMed ID: 24759174
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of a cholera toxin B subunit Porphyromonas gingivalis fimbrial antigen fusion protein expressed in E. coli.
Kim TG; Huy NX; Kim MY; Jeong DK; Jang YS; Yang MS; Langridge WH; Lee JY
Mol Biotechnol; 2009 Feb; 41(2):157-64. PubMed ID: 18807220
[TBL] [Abstract][Full Text] [Related]
15. Intranasal immunization with the cholera toxin B subunit-pneumococcal surface antigen A fusion protein induces protection against colonization with Streptococcus pneumoniae and has negligible impact on the nasopharyngeal and oral microbiota of mice.
Pimenta FC; Miyaji EN; Arêas AP; Oliveira ML; de Andrade AL; Ho PL; Hollingshead SK; Leite LC
Infect Immun; 2006 Aug; 74(8):4939-44. PubMed ID: 16861686
[TBL] [Abstract][Full Text] [Related]
16. Mucosal immunization with recombinant MOMP genetically linked with modified cholera toxin confers protection against Chlamydia trachomatis infection.
Singh SR; Hulett K; Pillai SR; Dennis VA; Oh MK; Scissum-Gunn K
Vaccine; 2006 Feb; 24(8):1213-24. PubMed ID: 16194585
[TBL] [Abstract][Full Text] [Related]
17. Expression of a pertussis toxin S1 fragment by inducible promoters in oral Streptococcus and the induction of immune responses during oral colonization in mice.
Mallaley PP; Halperin SA; Morris A; MacMillan A; Lee SF
Can J Microbiol; 2006 May; 52(5):436-44. PubMed ID: 16699568
[TBL] [Abstract][Full Text] [Related]
18. Oral immunization with recombinant Lactococcus lactis delivering a multi-epitope antigen CTB-UE attenuates Helicobacter pylori infection in mice.
Li X; Xing Y; Guo L; Lv X; Song H; Xi T
Pathog Dis; 2014 Oct; 72(1):78-86. PubMed ID: 24687988
[TBL] [Abstract][Full Text] [Related]
19. Cell-penetrating peptide-linked polymers as carriers for mucosal vaccine delivery.
Sakuma S; Suita M; Inoue S; Marui Y; Nishida K; Masaoka Y; Kataoka M; Yamashita S; Nakajima N; Shinkai N; Yamauchi H; Hiwatari K; Tachikawa H; Kimura R; Uto T; Baba M
Mol Pharm; 2012 Oct; 9(10):2933-41. PubMed ID: 22953762
[TBL] [Abstract][Full Text] [Related]
20. A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques.
Egan MA; Chong SY; Hagen M; Megati S; Schadeck EB; Piacente P; Ma BJ; Montefiori DC; Haynes BF; Israel ZR; Eldridge JH; Staats HF
Vaccine; 2004 Sep; 22(27-28):3774-88. PubMed ID: 15315859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
